drugset
drugset / Trial / NCT05124340

Safety and Tuberculin Conversion Following BCG Vaccination

NCT05124340 ↗

Phase 2 Completed 220 enrolled PT Bio Farma Dr. Soetomo General Hospital · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

The study is an bridging study, observer-blind, randomized, controlled prospective intervention study. The primary objective is evaluate the safety of BCG Vaccine Vial (Bio Farma).

Timeline

Start
2021-12-01
Primary completion
2022-05-31
Completion
2022-07-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator BCG ampoule vaccine Vaccine — Other
Subject BCG vial vaccine Vaccine — Other

Indications

No indication recorded.